Hycamtin

Rhabdomyosarcoma, Lymphoma, Malignant neoplasm of ovary + 5 more
Treatment
3 FDA approvals
20 Active Studies for Hycamtin

What is Hycamtin

TopotecanThe Generic name of this drug
Treatment SummaryAn antineoplastic agent used to treat ovarian cancer. It stops the growth of cancer cells by blocking the enzymes that help them replicate and divide.
Hycamtinis the brand name
image of different drug pills on a surface
Hycamtin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Hycamtin
Topotecan
1996
29

Approved as Treatment by the FDA

Topotecan, also known as Hycamtin, is approved by the FDA for 3 uses such as Malignant neoplasm of ovary and refractory, metastatic Ovarian cancer .
Malignant neoplasm of ovary
refractory, metastatic Ovarian cancer
Metastatic Cervical Cancer
Used to treat Metastatic Cervical Cancer in combination with Cisplatin

Effectiveness

How Hycamtin Affects PatientsTopotecan is a medication derived from a tree called Camptotheca acuminata and works by stopping cancer cells from growing. It does this by blocking the activity of an enzyme (DNA topoisomerase) that helps the cells replicate and survive. As this medication affects the growth of both healthy and cancer cells, other side effects may occur. Topotecan is not a prodrug and can be taken in its active form.
How Hycamtin works in the bodyTopotecan works by preventing the repair of single strand breaks in DNA. It does this by blocking the enzyme that would normally repair the breaks. This enzyme is known as topoisomerase I. When the breaks cannot be repaired, they form double strand breaks which are too severe for the cell to repair, leading to cell death. Topotecan works by attaching itself to the enzyme and the DNA, stopping the repair process.

When to interrupt dosage

The suggested measure of Hycamtin is contingent upon the identified affliction, including Malignant neoplasm of ovary, Lymphoma and metastatic Rhabdomyosarcoma. The magnitude of dosage is contingent upon the system of delivery featured in the table beneath.
Condition
Dosage
Administration
Malignant Neoplasms
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Lymphoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Malignant neoplasm of ovary
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
refractory CNS malignancy
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Rhabdomyosarcoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Sarcoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Acute Myeloid Leukemia
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Neuroblastoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral

Warnings

There are 20 known major drug interactions with Hycamtin.
Common Hycamtin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with Abatacept.
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Topotecan.
Abetimus
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with Abetimus.
Hycamtin Toxicity & Overdose RiskTaking too much of this medication may cause a decrease in healthy blood cells produced in the bone marrow.
image of a doctor in a lab doing drug, clinical research

Hycamtin Novel Uses: Which Conditions Have a Clinical Trial Featuring Hycamtin?

336 clinical trials are currently underway to investigate the potential of Hycamtin for treating Malignant Neoplasm of Ovary, Malignant Neoplasms and Metastatic Rhabdomyosarcoma.
Condition
Clinical Trials
Trial Phases
Acute Myeloid Leukemia
266 Actively Recruiting
Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1
Neuroblastoma
0 Actively Recruiting
Malignant neoplasm of ovary
0 Actively Recruiting
Lymphoma
0 Actively Recruiting
Rhabdomyosarcoma
0 Actively Recruiting
refractory CNS malignancy
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Sarcoma
1 Actively Recruiting
Phase 2

Patient Q&A Section about hycamtin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How effective is Hycamtin?

"At one year, 33 percent of patients treated with oral topotecan were still alive, compared to 29 percent of those treated with IV topotecan. Two years after treatment, 12 percent of those who had received oral topotecan were alive, compared to 7 percent of those treated with IV topotecan."

Answered by AI

What is topotecan used for?

"This medicine is used to treat metastatic cancer of the ovaries and small cell lung cancer."

Answered by AI

What is Hycamtin used for?

"This medication is used to treat small cell lung cancer. Its mechanism of action is either killing cancer cells or slowing their growth."

Answered by AI

Who manufactures Hycamtin?

"Hycamtin is a drug manufactured by GlaxoSmithKline that garnered $203.5 million in sales in 2003. It is approved by the FDA to treat ovarian cancers after failure of first-line chemotherapy, and it is the only drug approved by the FDA to treat small-cell lung cancers after failure of first-line chemotherapy."

Answered by AI

Clinical Trials for Hycamtin

Image of OHSU Knight Cancer Institute in Portland, United States.

Fludarabine + Cytarabine + Idarubicin + Venetoclax for Acute Myeloid Leukemia

18 - 65
All Sexes
Portland, OR
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.
Phase 2
Waitlist Available
OHSU Knight Cancer InstituteCurtis A Lachowiez
Image of Brigham and Women's Hospital in Boston, United States.

Tagraxofusp + Venetoclax + Azacitidine for Acute Myeloid Leukemia

18+
All Sexes
Boston, MA
The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence. The names of the study drugs involved in this study are: * Tagraxofusp (a type of CD123-directed cytotoxin) * Azacitidine (a type of standard of care cytidine nucleoside analog) * Venetoclax (a type of standard of care BCL-2 inhibitor)
Phase 1 & 2
Recruiting
Brigham and Women's Hospital (+1 Sites)Jacqueline Garcia, MDStemline Therapeutics, Inc.
Have you considered Hycamtin clinical trials? We made a collection of clinical trials featuring Hycamtin, we think they might fit your search criteria.Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Treatment Intensity for Acute Myeloid Leukemia

18+
All Sexes
Seattle, WA
This clinical trial studies whether less fit adults with acute myeloid leukemia (AML) or myeloid neoplasms are willing to let a computer program decide (randomization) whether they receive lower- or higher-intensity chemotherapy. Historically, treatment decision-making for patients with AML or myeloid neoplasms has divided patients into two categories, with patients considered fit receiving intensive "curative" chemotherapy, and patients considered unfit, such as older patients with a higher risk of early death from therapy, receiving non-intensive "palliative" therapy or no therapy. With the introduction of new treatment agents, it has become difficult to determine the difference between intensive and non-intensive therapy, especially for patients considered unfit for whom treatment-related side effects remain a concern. Treatment intensity is best identified through randomized trials but often patients are unwilling to undergo randomization due to preset beliefs. However, with improved supportive care and the awareness that new treatment agents may have similar risks as intensive therapy, it may be possible that more patients are willing to be randomized. This may help identify the best treatment intensity for less fit adults with AML or myeloid neoplasms, which may improve outcomes.
Waitlist Available
Has No Placebo
Fred Hutch/University of Washington Cancer ConsortiumJacob Appelbaum, MD, PhD
Image of Houston Methodist Neal Cancer Center in Houston, United States.

Hypomethylating Agents vs. Intensive Chemotherapy for Acute Myeloid Leukemia

18+
All Sexes
Houston, TX
This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA)-for assessing measurable residual disease (MRD) in patients with newly diagnosed acute myeloid leukemia (AML). The study compares the efficacy of hypomethylating agent (HMA)-based therapy versus intensive induction chemotherapy, using the 5hmC biomarker to guide post-induction treatment decisions. Approximately 112 adult patients will be enrolled and assigned to treatment arms based on a stratified sampling scheme. Blood samples will be collected at defined intervals to assess MRD status. Primary endpoints include minimal residual disease (MRD) negativity rate, duration of remission, event-free survival (EFS), and overall survival (OS).
Phase 2
Waitlist Available
Houston Methodist Neal Cancer CenterShilpan Shah, MD
Image of Texas Children's Cancer and Hematology Center in Houston, United States.

Combination Therapy for Pediatric Acute Myeloid Leukemia

1 - 30
All Sexes
Houston, TX
This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at intermediate-risk (IR) and high-risk (HR) of relapse. The goal is to achieve similar or better survival with chemotherapy cycles that are intensive but less likely to cause long-term complications. Patients will enroll on this trial at the end of their first induction cycle. The two cycles to be substituted are: * "Ida-FLA" (idarubicin+fludarabine/cytarabine) as Induction 2 * "VIA" (venetoclax+idarubicin+cytarabine) as Intensification 1 of the HR treatment regimen, and Intensification 2 of the IR treatment backbone. Researchers will evaluate side effects and outcomes for up to three years after enrollment. Participants will also have the opportunity to participate in optional research studies including patient surveys and blood and bone marrow sample testing.
Phase < 1
Recruiting
Texas Children's Cancer and Hematology Center
Have you considered Hycamtin clinical trials? We made a collection of clinical trials featuring Hycamtin, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

CMV-MVA Triplex Vaccine for Cancer

18 - 75
All Sexes
Duarte, CA
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Phase 1
Waitlist Available
City of Hope Medical Center (+2 Sites)Ryotaro Nakamura
Image of University of Vermont Medical Center in Burlington, United States.

Dexamethasone + Venetoclax-based Therapy for Acute Myeloid Leukemia

18+
All Sexes
Burlington, VT
This study is investigating whether adding dexamethasone, an anti-inflammatory medication, to a standard venetoclax-based low-intensity therapy (LIT) is safe and well-tolerated in patients with newly diagnosed Acute Myeloid Leukemia (AML) who are not eligible for intensive chemotherapy. Study Goals Primary Goal: To assess the safety and tolerability of dexamethasone in combination with venetoclax-based LIT. Secondary Goal: To evaluate how this treatment affects patients' quality of life using surveys. Exploratory Goal: To measure the treatment response, including remission rates and signs of minimal residual disease. What Happens in the Study? Patients will receive treatment over six cycles. Dexamethasone is given in different doses during the first six cycles along with venetoclax and another standard chemotherapy drug.
Phase 1
Waitlist Available
University of Vermont Medical Center
Image of Masonic Cancer Center in Minneapolis, United States.

Bortezomib + CPX-351 for Acute Myeloid Leukemia

18+
All Sexes
Minneapolis, MN
This is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabine) for the treatment of newly-diagnosed TP53-mutated acute myeloid leukemia (TP53m AML). The primary endpoint of the study is to define safety/tolerability (phase I) and preliminary efficacy profile (phase II) of the treatment. The secondary endpoints of interest are complete remission (CR) rate, detectable minimal residual disease (MRD) status, overall response rate (ORR), rate of allogeneic hematopoietic cell transplantation (allo-HCT), treatment-related mortality (TRM), overall survival (OS), achievement of complete remission anytime in 1 year, and disease-free survival (DFS) at 1 year and 2 years. All the patient outcomes assessments will be performed as part of standard-of-care AML management. The hypothesis is the combination of bortezomib and CPX-351 will have an acceptable safety profile in this patient population based on the data from previous studies. The treatment will attenuate Nuclear Factor kB pathway activation in these cells and eradicate TP53m leukemia stem cells (LSC) leading to increased response rate and survival in these patients.
Phase 1 & 2
Recruiting
Masonic Cancer Center
Have you considered Hycamtin clinical trials? We made a collection of clinical trials featuring Hycamtin, we think they might fit your search criteria.Go to Trials